2nd Obesity and Weight Loss Drug Development Summit Europe

Memo

Uncovering Innovative Targets, Emerging Combinations and Patient Phenotyping Approaches to Drive Tolerable, Differentiated and Long-Term Efficacious Therapies Through the Clinic URLs:Brochure: https://go.evvnt.com/3760195-0?pid=5569Tickets: https://go.evvnt.com/3760195-2?pid=5569 Date and Time: On Wed, 28 Oct 2026 07:30 - Thu, 29 Oct 2026 16:15 Venue Details: HYPERION Hotel Munchen, Truderinger Str. 13, 81677, Munchen, Germany Category: Conferences | Science, Health and Medicine | Pharmaceuticals Prices:Drug Developer Pricing - Full Access Pass: EUR 2899.00,Academic Pricing - Full Access Pass: EUR 2499.00,Service Provider Pricing - Full Access Pass: EUR 3499.00 Speakers: Jacob Jepsen, Chief Scientific Officer, Alveus Therapeutics, Philip Larsen, Chief Executive Officer, Antag Therapeutics, Steffen-Sebastian Bolz, Chief Scientific Officer, Alphaia Pharma, Paul Little, Chief Executive Officer, Atrogi, Matthijs van Haren, Founder and Chief Scientific Officer, Cantoni Therapeutics, Robert Mamoun, Co-Founder and Chief Executive Officer, Ciloa, Martin Brenner, Chief Executive and Chief Scientific Officer, iBio, Brent Meadows, Chief Business Officer, Senovia Biosciences, Xavier Jacq, Chief Scientific Officer, MitoRx Therapeutics, Daniel Markgraf, Head of Laboratory, Boehringer Ingelheim, Volker Mack, Senior Principal Scientist, Boehringer Ingelheim, Daniel de la Torre, Vice President, Research and Development, Constructive Bio, Saleha Patel, Head, Pipeline and Commercialisation Strategy Operations, Constructive Bio, Ohad Yogev, Vice President, Discovery, ScionXBio, Martin Hey-Mogensen, Scientific Director, Emerging Obesity Mechanism Global Research, Novo Nordisk, Lora Heisler, Director of Research, Rowett Institute of Nutrition and Health, University of Aberdeen